Navigation Links
Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents

NEW YORK, Sept. 10 /PRNewswire/ -- In a major victory for its client, Applera Corporation, a global leader in DNA sequencing technologies, Weil, Gotshal & Manges LLP won a summary judgment ruling invalidating three key contested life sciences patents. In the action, Enzo Biochem, Inc., had claimed that Applera's DNA sequencing reagents and instruments infringed the patents in question.

In a detailed 49-page Ruling, the Honorable Janet Bond Arterton of the United States District Court for the District of Connecticut concluded that the three patents were invalid for two separate reasons: first, that the patents were fatally indefinite because they fail to provide the public with adequate guidance of what is and what is not covered; and second that the patents were not novel because prior scientific publications described the same subject matter.

The case had been widely followed in the biotechnology industry because Applera's DNA sequencing reagents and instruments are core technologies enabling basic research into fundamental biological processes, as well as in applied fields such as diagnostic or forensic research.

The Weil Gotshal team was led by partners Nicholas Groombridge and Elizabeth Stotland Weiswasser. Mr. Groombridge, who late last year obtained the noteworthy trial judgment transferring inventorship and ownership of the U.S. patent that protected Imclone's blockbuster pharmaceutical, Erbitux(TM), argued the anticipation motion and commented, "We were gratified by the Court's ruling, which confirmed that these patents were not valid. When a company stands up to fight a patent, there is a clear benefit to the industry and consumers. The life sciences community, and the people and patients that it serves, owe a debt of gratitude to Applera for obtaining this win." Added Ms. Weiswasser, who argued the indefiniteness motion, "Judge Arterton's opinion carefully analyzes the patents and properly concludes that they are invalid."

About Weil, Gotshal & Manges

Weil, Gotshal & Manges LLP is an international law firm of 1,200 lawyers, including approximately 300 partners. Weil Gotshal is headquartered in New York, with offices in Austin, Boston, Budapest, Dallas, Frankfurt, Houston, London, Miami, Munich, Paris, Prague, Providence, Shanghai, Silicon Valley, Warsaw, Washington DC and Wilmington, and opening in Hong Kong in October 2007. Weil Gotshal's Intellectual Property Litigation practice was honored as the leading practice of its kind by Chambers USA with its 2007 Award of Excellence.

For more, contact: Mike Ford, Media Relations Manager

(212) 833-3999

Rubenstein Associates, Rhonda Walker


SOURCE Weil, Gotshal & Manges LLP
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer
2. Wisconsin building toward the major leagues of venture capital
3. Six things to consider before a major software implementation
4. New company eyes major ethanol production facility
5. Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot
6. University of Michigan plans major stem cell research center
7. BellBrook Labs gets major research funding
8. API announces major healthcare contracts
9. Top 20 big pharmas represent majority of world pharma market
10. Researchers report major advance in gene therapy technique
11. TrafficCast secures $2M from Phenomenelle Angels, NEW Capital Fund
Post Your Comments:
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... event of the year and one of the premier annual events for pharmaceutical ... ran from 8–11 November 2015, where ISPE hosted the largest number of attendees ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
Breaking Biology Technology:
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/11/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology company ... to announce that it will be a Sponsor of the ... be held November 17-19 in Hamburg , ... iMedNet , MedNet,s easy-to-use, proven and affordable ... been able to deliver time and cost savings of up ...
(Date:11/9/2015)... JOSE, Calif. , Nov. 9, 2015  Synaptics ... human interface solutions, today announced broader entry into the ... vehicle-specific solutions that match the pace of consumer electronics ... and biometric sensors are ideal for the automotive industry ... vehicle. Europe , ...
Breaking Biology News(10 mins):